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Abstract
Background: Selected microRNAs (miRNAs) that are abnormally expressed in the serum of patients with lung
cancer have recently been proposed as biomarkers of this disease. The measurement of circulating miRNAs,
however, requires a highly reliable quantification method. Quantitative real-time PCR (qPCR) is the most commonly
used method, but it lacks reliable endogenous reference miRNAs for normalization of results in biofluids. When
used in absolute quantification, it must rely on the use of external calibrators. Droplet digital PCR (ddPCR) is a
recently introduced technology that overcomes the normalization issue and may facilitate miRNA measurement.
Here we compared the performance of absolute qPCR and ddPCR techniques for quantifying selected miRNAs in
the serum.
Results: In the first experiment, three miRNAs, proposed in the literature as lung cancer biomarkers (miR-21,
miR-126 and let-7a), were analyzed in a set of 15 human serum samples. Four independent qPCR and four
independent ddPCR amplifications were done on the same samples and used to estimate the precision and
correlation of miRNA measurements obtained with the two techniques. The precision of the two methods was
evaluated by calculating the Coefficient of Variation (CV) of the four independent measurements obtained with
each technique. The CV was similar or smaller in ddPCR than in qPCR for all miRNAs tested, and was significantly
smaller for let-7a (p = 0.028). Linear regression analysis of the miRNA values obtained with qPCR and ddPCR
showed strong correlation (p < 0.001).
To validate the correlation obtained with the two techniques in the first experiment, in a second experiment
the same miRNAs were measured in a larger cohort (70 human serum samples) by both qPCR and ddPCR. The
correlation of miRNA analyses with the two methods was significant for all three miRNAs. Moreover, in our
experiments the ddPCR technique had higher throughput than qPCR, at a similar cost-per-sample.
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Conclusions: Analyses of serum miRNAs performed with qPCR and ddPCR were largely concordant. Both qPCR and
ddPCR can reliably be used to quantify circulating miRNAs, however, ddPCR revealed similar or greater precision
and higher throughput of analysis.
Keywords: microRNAs, Lung cancer, Serum biomarkers, qPCR, Droplet digital PCR
Abbreviations: CV, Coefficient of variation; ddPCR, Droplet digital PCR; miRNA(s), microRNA(s); qPCR, Quantitative
real-time PCR
Background
In recent years efforts have been made to find new ap-
proaches for early diagnosis of lung cancer, as the prog-
nosis of this disease strongly correlates with stage at the
time of diagnosis. Low-dose computed tomography (CT)
screening, the only lung cancer screening method en-
dorsed by leading cancer organizations [1–3], has uncer-
tain applicability on a population level as a public health
measure, due to high cost, undefined cost/benefit ratio,
high false-positive rate, overdiagnosis as well as radiation
exposure [4, 5]. Hence, novel methods capable of identi-
fying lung cancer at an early stage are urgently needed.
Recently, microRNAs (miRNAs) have been proposed
as a promising class of circulating cancer biomarkers:
they are very stable in biofluids and the plasma/serum
levels of several circulating miRNAs are aberrantly
expressed in many diseases, including numerous cancers
[6, 7]. miRNAs are small non-coding RNA molecules of
about 20–25 nucleotides that regulate gene expression
at the post-transcriptional level [8]. Circulating miRNAs
are either stored in particles (exosomes, microvesicles
and apoptotic bodies), or associated with RNA-binding
proteins or lipoproteins, which prevent their degrad-
ation. The abundance and variety of circulating miRNAs
suggest a role in cell-cell communication and their po-
tential exploitation as disease biomarkers [9–13]. Among
several miRNAs overexpressed in the serum of patients
with lung cancer, miR-21 is the most frequently pro-
posed as biomarker of this disease [14–19]. Other miR-
NAs, that appear to function as tumor suppressors, such
as miR-126 and let-7a, are down-regulated in lung can-
cer patients [20–22].
However, the use of circulating, cell-free, miRNAs as
biomarkers for diagnosis of cancer may be proposed
only if a reliable and sensitive method for miRNA quan-
tification is available. Quantitative real-time PCR (qPCR)
has to date represented the method of choice for this
purpose, as it can quantify nucleic acids. Depending on
the method used, a “relative” or an “absolute” measure-
ment can be obtained with qPCR, neither of which is de-
void of drawbacks. Relative quantification of circulating
miRNAs by qPCR, although commonly applied, is ham-
pered by the difficulty of finding reliable endogenous
reference genes in the serum, as currently there is no
general consensus [23, 24]. On the other hand, absolute
quantification is based on calibration curves that are
built using known amounts of external calibrators, usu-
ally synthetic molecules with the same sequence as the
gene of interest. The calibrator concentration however
relies on quantification methods and serial dilutions that
are themselves prone to uncertainties; moreover, the
calibrator amplification kinetics may not reflect that of
the endogenous molecules due to differences in matrix
composition [25]. Thus, also absolute quantification of a
target gene by qPCR is “relative” to the exact quantifica-
tion of the calibrator [26–29].
Droplet digital PCR (ddPCR) is a recently introduced
technology that may facilitate miRNA measurement.
The ddPCR technique is based on partitioning of the
sample into thousands of micro-reactions of defined vol-
ume [30]. After the PCR reaction, each droplet either
does or does not contain the nucleic acid of interest,
thus allowing estimation of the number of molecules in
the reaction under the assumption of a Poisson distribu-
tion. Results are expressed as target copies per microliter
of reaction [31]. In comparison with qPCR, the ddPCR
technique has some favorable features, among which: 1)
it performs absolute quantification based on the princi-
ples of sample partitioning and Poisson statistics, thus
overcoming the normalization and calibrator issues [32];
2) it has shown increased precision [33] and sensitivity
in detecting low target copies [34]; 3) it is relatively
insensitive to potential PCR inhibitors [35–37]; 4) it
directly provides the result of the analysis expressed as
number of copies of target per microliter of reaction
(with confidence intervals) [38].
In the present study, carried out at the University of
Insubria and the Varese University Hospital, we aimed to
compare the performance of the qPCR and ddPCR plat-
forms for quantitative measurement of specific miRNAs
in human serum. Three endogenous miRNAs, miR-21,
miR-126 and let-7a, which represent candidate biomarkers
of human lung cancer [14–22], were examined. We se-
lected these three miRNAs, among numerous miRNAs
currently under investigation in many laboratories, for
their potential ability to identify individuals with early
stage lung cancer [14–22]. An equal number of therapy-
naïve, early stage lung cancer patients and age, sex and
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smoking habit matched controls were included in this
study, aiming to explore the performance of the two tech-
nologies over the range of miRNA levels to be determined
in future studies of human serum samples of interest.
Comparison of results of microRNAs expression between
patients and controls, as well as analysis of results related
to lung cancer detection, are beyond the purpose of the
present paper.
Study design
We carried out two experiments. In the first (Fig. 1a), 15
serum samples [7 from patients with early stage lung
cancer (stage I and II [39]); 8 from control individuals]
were used to compare the precision of miRNA measure-
ments performed with qPCR and ddPCR, and to assess
the correlation of measurements obtained with the two
methods. In the second experiment (Fig. 1b) we investi-
gated the correlation between the two methods of
miRNA analysis in a larger number of samples (35 from
early stage lung cancer patients; 35 from controls).
Results
In the first experiment (Fig. 1a), four independent ana-
lyses for each technique were performed on each cDNA
from 15 samples. Each of the four analyses in qPCR was
done in triplicate, for a total of 180 amplifications. We
found that the trend of expression of miRNAs under
study was similar with the two techniques, as can be
seen by comparative inspection of scatter plots in Fig. 2.
Notably, for miR-126 and let-7a, the samples showed
higher values in qPCR as compared to ddPCR: the esti-
mated copy numbers in qPCR were approximately 2.4
and 3.9 fold greater, respectively, than in ddPCR (Fig. 2).
The dispersion of values of the four analyses per-
formed on the same 15 cDNAs was frequently higher
with qPCR than with ddPCR (Fig. 2). In the first experi-
ment, the precision of miRNA quantification, measured
by the Coefficient of Variation (CV), was significantly
better for ddPCR compared to qPCR for let-7a (p = 0.028),
while it was not significantly different for miR-21 and
miR-126 (Table 1).
Linear regression analysis indicated a significant cor-
relation between qPCR and ddPCR values (Fig. 3). The
R-square was 0.963 for miR-21, 0.984 for miR-126 and
0.978 for let-7a (p < 0.0001 for all regressions). However,
the slope (b) of the regression line for miR-126 (b = 0.420
[CI 95 % 0.391–0.452]) and let-7a (b = 0.2561 [CI 95 %
0.234–0.278]) was significantly lower than one, due to the
lower number of copies measured by ddPCR as compared
to what estimated with the external calibrator in qPCR.
To verify these systematic differences between qPCR
and ddPCR measurements, we quantified by ddPCR the
cDNAs of the specific calibrators used to build the
calibration curves for qPCR and found a lower concen-
tration than the theoretical one that had been used for
calculations in qPCR (data not shown).
In the second experiment, evaluating a cohort of 35
samples from early stage lung cancer patients and 35
from matched controls, again we found significant cor-
relation between qPCR and ddPCR values (R-square =
0.948 for miR-21, 0.954 for miR-126 and 0.949 for let-7a;
p < 0.0001 for all regressions) (Fig. 4). Consistently, the
slopes for miR-126 and let-7a were confirmed to be sig-
nificantly lower than 1 (b = 0.695 [CI 95 % 0.658–0.731]
and b = 0.347 [CI 95 % 0.328–0.366], respectively).
Discussion
Finding a reliable and sensitive method for quantitation
of circulating miRNAs is key to their use as cancer bio-
markers. Here we compared the performance of qPCR
and ddPCR over the range of miRNA levels to be deter-
mined in serum samples of lung cancer patients and
controls. For qPCR, the relative quantification method is
the most commonly used in the literature, however the
lack of reliable endogenous reference miRNAs in bio-
fluids and inability to provide a number of copies of a
specific target as the output of analysis, render relative
quantification largely unpractical in the perspective of
developing a test for clinical use [23].
In qPCR, the absolute quantification method can be
used to measure miRNAs of interest in the samples. We
Fig. 1 Workflow of the experiments. a In the first experiment, for
determination of each miRNA of interest (miR-21, miR-126 and
let-7a) in each of 15 serum samples, we performed 4 independent
qPCRs and 4 independent ddPCRs. b In the second experiment, the
miRNAs of interest were measured with qPCR and ddPCR in 70
serum samples. All qPCRs were run in triplicate; ddPCRs were run as
single reactions
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estimated the number of target copies in unknown
samples based on their Cq compared to that of a stand-
ard calibrator. This is a crucial and often underestimated
problem, as in qPCR it is assumed that in the calibrator
the nominal and measured copies are equivalent in
number. The qPCR method relies on accurate quantifica-
tion of the number of copies of the calibrator, and assumes
that no loss of calibrator molecules occurs during the
whole procedure. However, errors/imprecisions are pos-
sible at several levels [40]: 1) during initial quantification of
Fig. 2 ddPCR frequently shows greater precision compared to qPCR for quantifying miRNAs under study. Scatter plots showing the expression
values of the selected miRNAs, by qPCR (panels on the left) and ddPCR (panels on the right), in the 15 samples (first experiment). Four independent
amplifications were performed for each sample in each technique. For qPCR each dot represents the mean of the technical triplicates. The mean and
the standard deviation of values obtained from the four independent measurements are shown for each of the 15 samples
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the standard; 2) during resuspension and preparation of
serial dilutions; 3) during reverse transcription (if working
on RNA); 4) during amplification itself. Most methods for
evaluating nucleic acids concentrations are based on ab-
sorbance (optical density), fluorimetric measurements and
gel electrophoresis. None of them is devoid of impreci-
sions; they may not reveal incomplete or partially degraded
copies within the sample, or they may still be relative to a
standard for accurate quantification [41]. Moreover, cali-
bration standards are often delivered after quantification
from the manufacturing company in a dry form, from
which the samples need to be resuspended and undergo
several dilution steps to reach the concentration useful for
calibration purposes. Reverse transcription is a critical step
that can account for variability in sample quantification
[42]. Also the amplification step can be subject to variabil-
ity, due to suboptimal efficiency of the assay or to the pres-
ence of inhibitors [25–29]. In addition, PCR efficiency of
pure synthetic standards may differ from that of serum
samples, possibly containing inhibitors [25].
In ddPCR, PCR-positive and PCR-negative droplets
are counted at the end of the amplification procedure to
directly provide absolute quantification of the target
DNA in digital form. The output of analysis is given in
copies per microliter of reaction, with 95 % confidence
intervals. The ddPCR system allows measurement of
DNA copy numbers with remarkable precision; it has been
proposed as a method for quantitation of reference mate-
rials for the construction of calibration curves [43, 44].
In the present study the results of miRNA analyses
with the two techniques significantly correlated. For
each of the three miRNAs investigated, the correlation
between qPCR and ddPCR measurements was similar
comparing the first and the second experiment (Figs. 3
and 4). However, we observed that for miR-126 and let-
7a, ddPCR yielded respectively 2.4- and 3.9-fold lower
values than qPCR. These discrepancies may be due to a
combination of factors, mentioned above, that can affect
the qPCR calibration curve. Suboptimal efficiency of ret-
rotranscription, could possibly account for the lower
miRNA values estimated by ddPCR [42]. By applying ex-
clusively qPCR to the construction of the calibration
curve and to the determination of target concentrations
in samples, these inaccuracies would go undetected. The
differences we observed in miRNA quantitation between
qPCR and ddPCR are comparable with those previously
published by other authors [45]. The fact that ddPCR
does not require a reference or a standard calibrator
curve for quantification, represents one of the main ad-
vantages of ddPCR over qPCR.
As for reproducibility of ddPCR analyses, we found
high correlation between duplicate ddPCR reactions (R-
square = 1; Additional file 1: Figure S1A). Moreover,
similar miRNA copy numbers were obtained when sam-
ples were measured at different times: immediately after
retrotranscription and after storage at −20 °C for an
average of 8 months (R-square = 0,979; Additional file 1:
Figure S1B). When we compared miRNA measurements
by ddPCR after two independent retrotranscription reac-
tions we found a slightly lower reproducibility (R-square =
0.9193; Additional file 1: Figure S1C). When we com-
pared ddPCR measurements of miRNA levels in the
same samples analyzed with an identical instrument
at another institution we also found similar results (data
not shown).
ddPCR averts the need for technical replicates [38],
because the sample is partitioned into thousands of
micro-reactions. This, in turn, accelerates the quantifica-
tion process, as more samples, or a higher number of
targets, can be analyzed on a single 96 multiwell plate.
Recently, instruments and reagents for target quantifica-
tion based on DNA binding dyes, such as EvaGreen,
have become available for digital PCR and have shown
results comparable to the use of hydrolysis probes in
digital PCR when applied to the quantification of circu-
lating miRNAs [46]. These technological features
allowed us to use total cDNA obtained with Exiqon Uni-
versal cDNA synthesis kit II and the same Exiqon LNA
primer assays to evaluate miRNA expression using both
qPCR and ddPCR platforms. Notably, the total cDNA
obtained from serum samples can be stored and pre-
served for future determinations of new potential target
miRNAs at later times.
It is important to note that the ddPCR method dis-
played less variability in replicate analyses than the
qPCR method (Fig. 2 and Table 1). It has also been pro-
posed that ddPCR might be less sensitive to differences
in sample quality and to the presence of PCR inhibitors,
two factors known to influence qPCR amplification effi-
ciency [36, 45, 47]. The fact that ddPCR is an end-point
analysis, and that absolute quantification relies on pres-
ence or absence of fluorescence in each droplet, rather
Table 1 Mean and standard deviation of Coefficients of
Variation of miR-21, miR-126 and let-7a determinations with
qPCR and ddPCR
n Coefficient of variation p*
Mean Std. deviation
Pair 1 miR-21 qPCR 15 11.040 5.4387 0.123
miR-21 ddPCR 15 8.319 3.2207
Pair 2 miR-126 qPCR 15 7.386 2.8837 0.675
miR-126 ddPCR 15 7.944 4.8446
Pair 3 let-7a qPCR 15 10.298 2.4077 0.028
let-7a ddPCR 15 7.992 3.2646
The data for this table were obtained by analyzing 15 samples with four
independent analyses with each technique
* paired samples t-test
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than the fluorescence levels during the reaction, makes
it a robust technique for determining circulating
biomarkers. All of these features should simplify the
comparison of values obtained with ddPCR assays in dif-
ferent laboratories, while comparison of qPCR results is
difficult, as the latter method relies on the use of calibra-
tors or endogenous reference miRNAs, on which there
is no consensus. Altogether, we found that the time
needed to complete a set of miRNA analyses, including
post-PCR processing of data (calculations for qPCR,
droplet analysis for ddPCR) was about 2-fold shorter
with ddPCR than with qPCR.
Finally, we estimated the direct cost, for the amplifica-
tion step only, for each miRNA determination in the
serum in our laboratory: about 3.33 Euro for qPCR
(overall cost for triplicate reactions) and about 3.66 Euro
for ddPCR. This cost included all necessary disposables
and reagents, starting from cDNA to completion of ana-
lysis, while the initial costs for instrument purchase were
not taken into account. Thus, in our setting, the price
per reaction was very similar with the two techniques.
Conclusions
We showed a statistically significant linear regression
between the quantitative determinations with qPCR and
ddPCR of selected circulating miRNAs proposed as lung
cancer biomarkers (miR-21, miR-126 and let-7a). Hence,
both techniques can reliably be used for quantification
of circulating miRNAs as potential biomarkers. Based on
the numerous determinations we made for these miR-
NAs, the recently introduced ddPCR technology com-
pared to qPCR showed similar or greater precision and
demonstrated to be a robust method for absolute quanti-
fication of selected miRNAs concentration in the serum.
Methods
Samples and miRNAs used in this study
Peripheral blood samples (5 mL) were obtained by
venipuncture from 70 volunteer adult subjects: 35
therapy-naïve patients with early lung cancer (stage I
and II) [39] and 35 age-matched controls (asymptomatic
smokers undergoing check-up evaluation). We measured
three miRNAs for which a role as cancer biomarkers has
been proposed (miR-21; miR-126; let-7a).
Comparison of qPCR and ddPCR
To compare the two methods of miRNA quantification,
we extracted total RNA and prepared cDNA starting
from each serum sample, obtained as outlined above. To
Fig. 3 Correlation between qPCR and ddPCR measurements in the
first experiment. miR-21, miR-126 and let-7a levels (copies/microliter)
were measured in 15 serum samples. Each dot represents the
average of 4 independent determinations
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ensure that intersample variability was kept to the mini-
mum, we worked using constant volumes throughout
the whole procedure, starting from serum to the final
amplification step.
First experiment
To compare the precision of miRNA measurements
performed with qPCR and ddPCR, and to assess the
correlation of the measurements obtained with the two
methods, cDNA from each of the 15 samples was
divided into aliquots that were used to perform four in-
dependent qPCR and four independent ddPCR analyses,
on different days. Each qPCR analysis was done in tripli-
cate and the average of the triplicate values represents
every single result of the qPCR analysis. For ddPCR, the
analysis of each miRNA in each sample was done as sin-
gle reaction (Fig. 1a). All data were expressed as copies/
μL of reaction. Copies were extrapolated from the stand-
ard curves for qPCR (see below) or directly represented
the output of the QuantaSoft software for ddPCR. How-
ever, also in the latter case, manual inspection of the
samples was performed to set the fluorescence threshold
and divide droplets not containing from droplets con-
taining the template. For each of the 15 samples, the
following three miRNAs were analyzed: miR-21, miR-
126 and let-7a, along with the relative quality controls
(spike-ins), to check for extraction and retrotranscrip-
tion efficiencies and presence of potential inhibitors, as
well as hemolysis indicators (miRNAs deriving from lysis
of red blood cells that may influence the measured
value).
Second experiment
Using both qPCR and ddPCR we quantified the level of
miR-21, miR-126 and let-7a in the serum samples of 35
patients with early stage lung cancer and 35 controls. In
this experiment a single analysis was performed for each
technique (in qPCR the value used for analyses is the
average of three technical replicates) and for each of the
three miRNAs of interest in each serum sample (Fig. 1b).
Quality control miRNAs were analyzed as described in
the first experiment.
Serum preparation and RNA extraction
Peripheral blood was collected using sterile tubes with-
out anticoagulant and left at room temperature to co-
agulate for a minimum of 30 and a maximum of 60 min.
Then serum was separated by centrifugation at 400 g for
8 min at 4 °C, was divided in 500 μL aliquots and stored
at −80 °C until total RNA extraction.
Purification of total RNA, including miRNAs, was per-
formed using the miRNeasy serum/plasma kit (Qiagen,
Milan, Italy), starting from 200 μL of serum and follow-
ing manufacturer’s instructions. One μg of MS2 phage
Fig. 4 Correlation between qPCR and ddPCR measurements in the
second experiment. miR-21, miR-126 and let-7a levels (copies/microliter)
were measured in 70 serum samples
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carrier RNA (Roche, Monza, Italy) and 1 μL of a mix of
UniSp2, UniSp4 and UniSp5 spike-ins (Exiqon, Euroclone,
Milan, Italy) were added just before the purification
process to assess efficiency of RNA purification and pres-
ence of possible PCR inhibitors. RNA was eluted from the
column with 14 μL of nuclease-free water and stored at
−80 °C.
Retrotranscription
Two μL of RNA were reverse transcribed to cDNA in
10 μL total reaction, using the Universal cDNA synthesis
kit II, as part of the miRCURY LNA™ Universal RT
microRNA PCR system (Exiqon, Euroclone, Milan, Italy)
according to the manufacturer’s instructions. For some
samples also a “no enzyme” control reaction was pre-
pared and subsequently analyzed by qPCR in parallel
with their retrotranscribed counterparts, to check for
“non miRNA specific” amplification. 0.5 μL of UniSp6
and cel-miR-39-3p spike-ins were added when assem-
bling the reactions for subsequent evaluation of effi-
ciency of the reverse transcription step. For the first
experiment, conducted on 15 serum samples, the cDNA
was prediluted 4-fold, split into four aliquots of 5.6 μL for
qPCR and four aliquots of 3 μL for ddPCR and stored at
−20 °C until use; this was made to avoid repeated freeze
and thawing of the cDNAs. For the second experiment,
conducted on 70 samples with single analyses, the cDNA
samples were stored at −20 °C undiluted.
Real-time qPCR
The cDNAs were diluted further 10 fold from the predi-
lutions (first experiment, 15 samples) or 40 fold from
undiluted reactions (second experiment, 70 samples) just
before use. Four microliter were used in each 10 μL
qPCR reaction, completed with the addition of 6 μL of
reaction mixture, composed of 1 μL of the specific miR-
CURY LNA PCR primer set and 5 μL of ExiLENT SYBR
Green master mix (both from Exiqon-Euroclone, Milan,
Italy). All reactions were performed in triplicate and the
values shown are means of these replicates (Fig. 1) A no
template control (NTC), where distilled water was added
instead of cDNA samples, was included for each reac-
tion mix prepared. A CFX96 realtime PCR instrument
(Biorad, Milan, Italy) was used, following the manufac-
turer’s instructions for cycling conditions [95 °C for
10 min, followed by 40 cycles of 95 °C for 10 s and 60 °C
for 1 min (1.6 °C/s ramp rate)].
The samples were monitored for hemolysis by cal-
culating the difference between the Cq values of miR-
23a and miR-451a, evaluated by qPCR, according to
the Exiqon guidelines. Samples were considered at
risk of hemolysis when their ΔCq (CqmiR-23a - CqmiR-451a)
was > 5.
Standard curve construction and sample absolute
quantification with qPCR
Three unmodified oligoribonucleotides corresponding to
hsa-miR-21-5p (UAGCUUAUCAGACUGAUGUUGA),
hsa-miR-126-3p (UCGUACCGUGAGUAAUAAUGCG)
and hsa-let-7a-5p (UGAGGUAGUAGGUUGUAUAGU
U) were synthesized (Eurofins Genomics, Milan, Italy).
Different dilutions of oligoribonucleotides in RNase-free
water were prepared and the appropriate dilution (6 ×
104 copies) was reverse transcribed to cDNA in 10 μL
total reaction, using the Universal cDNA synthesis kit II,
as part of the miRCURY LNA™ Universal RT microRNA
PCR system (Exiqon, Euroclone, Milan, Italy). A two-
fold dilution series over nine points were prepared from
the cDNA, starting from a dilution at 2000 copies/μL,
then the nine dilutions were used as templates for qPCR.
Each point was performed in triplicate. The standard
curve was constructed by plotting Cq values against the
logarithmic concentration of the calibrator oligoribonu-
cleotides. The amount of an unknown sample was quan-
tified by interpolating the Cq values in the standard
curve.
Droplet digital PCR
The cDNAs were diluted as described in the previous
section and 5 μL were used in each ddPCR reaction,
adding the desired miRCURY LNA PCR primer set at
the appropriate dilution (Table 2), experimentally deter-
mined by testing two different volumes of primers,
10 μL of QX200 EvaGreen ddPCR Supermix (Biorad,
Milan, Italy) and nuclease-free water up to 20 μL. A no
template control (NTC), where distilled water was added
instead of cDNA samples, was routinely included for
each reaction mix prepared. Each 20 μl ddPCR reaction
was loaded into an 8-channel droplet generation cart-
ridge (Biorad, Milan, Italy); 70 μL of QX200 Droplet
generation oil (Biorad, Milan, Italy) was added into the
appropriate wells and the cartridge was loaded in the
QX200™ Droplet Generator (Biorad, Milan, Italy) to
generate the emulsion. The resulting droplets were
transferred to a 96-well plate (Eppendorf) with a Rainin
multichannel pipette, the plate sealed with Pierceable foil
(Biorad, Milan, Italy) and amplified by standard PCR
using a Mastercycler® ep (Eppendorf ). Cycling conditions
were: 95 °C for 5 min, followed by 40 cycles of 95 °C for
30 s and 60 °C for 1 min, followed by signal stabilization
Table 2 Primer sets used in the study and volumes for ddPCR
Candidate miRNAs under study Exiqon ID Volume used in
ddPCR (microliters)
miR-21-5p 204230 1
miR-126-3p 204227 0.5
let-7a-5p 205727 1
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steps (4 °C for 5 min, 90 °C for 5 min) and final hold at
4 °C. The ramp rate was 2 °C/s. After PCR, plates were
loaded into QX200™ Droplet Reader (Biorad, Milan, Italy)
for detection.
The resulting copies per microliter of reaction were
adjusted depending on the number of microliters of
cDNA used in qPCR and ddPCR before making compar-
isons between the two techniques.
Statistical analyses
Correlation between the qPCR and the ddPCR output
analyses was tested by linear regression model. The pre-
cision of miRNA measurements was estimated with the
Coefficient of Variation [CV = (SD/mean)*100] of quad-
ruplicate measures for each sample, for both qPCR and
ddPCR. The CVs of the two assays were compared by
t-test for paired data. A p value <0.05 was considered
statistically significant.
Data were analyzed with SPSS 10.6 software (Illinois,
USA).
Additional file
Additional file 1: Figure S1. Reproducibility of miR-126 quantification
by ddPCR: in 10 cDNA samples analysed in duplicate on the same day
(A); in 8 cDNA samples before and after storage at −20 °C for 8 months
(B); in 4 samples after two independent retrotranscription reactions (C).
(TIF 100 kb)
Acknowledgements
We are extremely grateful to Mr. Piero Francesco Macchi and Mrs. Carlotta
Biasini for their generous donation to support this study. We would like to
thank Dr. Sergio Marchini of Mario Negri Institute, Milan, for allowing
comparison of ddPCR instruments performance. EG and PDA are PhD
students of the “Biotechnology, Biosciences and Surgical Technology”
course at Università degli Studi dell’Insubria.
Funding
This work was supported by grants from: Fondazione Comunitaria del
Varesotto; Associazione PREDICA Onlus; PRIN 2010NECHBX_003; AIRC
(Associazione Italiana per la Ricerca sul Cancro IG15895). Cofunded by
donations from Mr. Piero Francesco Macchi and Mrs. Carlotta Biasini. These
funding bodies had no role in the design of the study, in the collection,
analysis, and interpretation of data and in writing the manuscript.
Availability of data and material
All data generated/analysed during the current study that are not already
included in this published article, are available from the corresponding
author on reasonable request.
Authors’ contributions
PC and AI were responsible for study conception and design, analysis and
interpretation of data and writing of the manuscript; EG did the
experimental work, analyses of experimental data, figures drawing and
critical reading of the manuscript; PDA contributed to the experimental
work; DMN contributed to study conception, to analysis of experimental data
and to the writing of the manuscript; NR, LD and AI provided and cared for
study patients and samples, collection and evaluation of clinical data; AP
analyzed the data, supervised the statistical analyses and contributed to the
writing of the manuscript. All authors discussed and commented the results
and gave their final approval for submission.
Competing interests
The authors declare that they have no competing interests.
Consent for publication
Not applicable.
Ethics approval and consent to participate
The Varese University Hospital Ethics Committee approved this study
(Protocol approval n. 37527). All participants provided informed consent to
use their samples for research purposes. Research was carried out in
compliance with the Helsinki Declaration.
Author details
1Department of Biotechnology and Life Sciences (DBSV) and “The Protein
Factory”, University of Insubria, Via JH Dunant, 3, 21100 Varese, Italy. 2The
Protein Factory, Centro Interuniversitario di Ricerca in Biotecnologie
Proteiche, Politecnico di Milano, ICRM-CNR Milano and University of Insubria,
Varese, Italy. 3Department of Surgical Sciences and Human Morphology,
DSCM, University of Insubria, Via Guicciardini, 9, 21100 Varese, Italy. 4Scientific
and Technological Pole, IRCCS MultiMedica, Milan, Italy. 5Department of
Public Health and Community Medicine, University of Verona, Verona, Italy.
Received: 23 February 2016 Accepted: 13 August 2016
References
1. Wender R, Fontham ET, Barrera Jr E, Colditz GA, Church TR, Ettinger DS,
Etzioni R, Flowers CR, Gazelle GS, Kelsey DK, et al. American Cancer Society
lung cancer screening guidelines. CA Cancer J Clin. 2013;63(2):107–17.
2. Jaklitsch MT, Jacobson FL, Austin JH, Field JK, Jett JR, Keshavjee S,
MacMahon H, Mulshine JL, Munden RF, Salgia R, et al. The American
Association for Thoracic Surgery guidelines for lung cancer screening using
low-dose computed tomography scans for lung cancer survivors and other
high-risk groups. J Thorac Cardiovasc Surg. 2012;144(1):33–8.
3. Detterbeck FC, Unger M. Screening for lung cancer: moving into a new era.
Ann Intern Med. 2014;160(5):363–4.
4. Strauss GM, Dominioni L. Chest X-ray screening for lung cancer:
overdiagnosis, endpoints, and randomized population trials. J Surg Oncol.
2013;108(5):294–300.
5. Dominioni L, Poli A, Mantovani W, Pisani S, Rotolo N, Paolucci M, Sessa F,
Conti V, D’Ambrosio V, Paddeu A, et al. Assessment of lung cancer mortality
reduction after chest X-ray screening in smokers: a population-based cohort
study in Varese, Italy. Lung Cancer. 2013;80(1):50–4.
6. Esquela-Kerscher A, Slack FJ. Oncomirs - microRNAs with a role in cancer.
Nat Rev Cancer. 2006;6(4):259–69.
7. Lujambio A, Lowe SW. The microcosmos of cancer. Nature. 2012;482(7385):
347–55.
8. Brodersen P, Voinnet O. Revisiting the principles of microRNA target
recognition and mode of action. Nat Rev Mol Cell Biol. 2009;10(2):141–8.
9. Arroyo JD, Chevillet JR, Kroh EM, Ruf IK, Pritchard CC, Gibson DF, Mitchell PS,
Bennett CF, Pogosova-Agadjanyan EL, Stirewalt DL, et al. Argonaute2
complexes carry a population of circulating microRNAs independent of
vesicles in human plasma. Proc Natl Acad Sci U S A. 2011;108(12):5003–8.
10. Valadi H, Ekstrom K, Bossios A, Sjostrand M, Lee JJ, Lotvall JO. Exosome-
mediated transfer of mRNAs and microRNAs is a novel mechanism of
genetic exchange between cells. Nat Cell Biol. 2007;9(6):654–9.
11. Vickers KC, Palmisano BT, Shoucri BM, Shamburek RD, Remaley AT.
MicroRNAs are transported in plasma and delivered to recipient cells by
high-density lipoproteins. Nat Cell Biol. 2011;13(4):423–33.
12. Zernecke A, Bidzhekov K, Noels H, Shagdarsuren E, Gan L, Denecke B,
Hristov M, Koppel T, Jahantigh MN, Lutgens E, et al. Delivery of
microRNA-126 by apoptotic bodies induces CXCL12-dependent vascular
protection. Sci Signal. 2009;2(100):ra81.
13. Zhang Y, Liu D, Chen X, Li J, Li L, Bian Z, Sun F, Lu J, Yin Y, Cai X, et al.
Secreted monocytic miR-150 enhances targeted endothelial cell migration.
Mol Cell. 2010;39(1):133–44.
14. Boeri M, Verri C, Conte D, Roz L, Modena P, Facchinetti F, Calabro E,
Croce CM, Pastorino U, Sozzi G. MicroRNA signatures in tissues and plasma
predict development and prognosis of computed tomography detected
lung cancer. Proc Natl Acad Sci U S A. 2011;108(9):3713–8.
Campomenosi et al. BMC Biotechnology  (2016) 16:60 Page 9 of 10
15. Hu Z, Chen X, Zhao Y, Tian T, Jin G, Shu Y, Chen Y, Xu L, Zen K, Zhang C,
et al. Serum microRNA signatures identified in a genome-wide serum
microRNA expression profiling predict survival of non-small-cell lung cancer.
J Clin Oncol. 2010;28(10):1721–6.
16. Le HB, Zhu WY, Chen DD, He JY, Huang YY, Liu XG, Zhang YK. Evaluation of
dynamic change of serum miR-21 and miR-24 in pre- and post-operative
lung carcinoma patients. Med Oncol. 2012;29(5):3190–7.
17. Ma J, Li N, Guarnera M, Jiang F. Quantification of Plasma miRNAs by Digital
PCR for Cancer Diagnosis. Biomark Insights. 2013;8:127–36.
18. Shen J, Liu Z, Todd NW, Zhang H, Liao J, Yu L, Guarnera MA, Li R, Cai L,
Zhan M, et al. Diagnosis of lung cancer in individuals with solitary
pulmonary nodules by plasma microRNA biomarkers. BMC Cancer.
2011;11:374.
19. Tang D, Shen Y, Wang M, Yang R, Wang Z, Sui A, Jiao W, Wang Y.
Identification of plasma microRNAs as novel noninvasive biomarkers for
early detection of lung cancer. Eur J Cancer Prev. 2013;22(6):540–8.
20. Bianchi F, Nicassio F, Marzi M, Belloni E, Dall’olio V, Bernard L, Pelosi G,
Maisonneuve P, Veronesi G, Di Fiore PP. A serum circulating miRNA
diagnostic test to identify asymptomatic high-risk individuals with early
stage lung cancer. EMBO Mol Med. 2011;3(8):495–503.
21. Jeong HC, Kim EK, Lee JH, Lee JM, Yoo HN, Kim JK. Aberrant expression of
let-7a miRNA in the blood of non-small cell lung cancer patients. Mol Med
Rep. 2011;4(2):383–7.
22. Shen J, Todd NW, Zhang H, Yu L, Lingxiao X, Mei Y, Guarnera M, Liao J,
Chou A, Lu CL, et al. Plasma microRNAs as potential biomarkers for
non-small-cell lung cancer. Lab Invest. 2011;91(4):579–87.
23. Sun Y, Zhang K, Fan G, Li J. Identification of circulating microRNAs as
biomarkers in cancers: what have we got? Clin Chem Lab Med.
2012;50(12):2121–6.
24. Peltier HJ, Latham GJ. Normalization of microRNA expression levels in
quantitative RT-PCR assays: identification of suitable reference RNA targets
in normal and cancerous human solid tissues. RNA. 2008;14(5):844–52.
25. Corbisier P, Pinheiro L, Mazoua S, Kortekaas AM, Chung PY, Gerganova T,
Roebben G, Emons H, Emslie K. DNA copy number concentration measured
by digital and droplet digital quantitative PCR using certified reference
materials. Anal Bioanal Chem. 2015;407(7):1831–40.
26. Lai KK, Cook L, Krantz EM, Corey L, Jerome KR. Calibration curves for
real-time PCR. Clin Chem. 2005;51(7):1132–6.
27. Gullett JC, Nolte FS. Quantitative nucleic acid amplification methods for viral
infections. Clin Chem. 2015;61(1):72–8.
28. Chaouachi M, Berard A, Said K. Relative quantification in seed GMO analysis:
state of art and bottlenecks. Transgenic Res. 2013;22(3):461–76.
29. Botes M, de Kwaadsteniet M, Cloete TE. Application of quantitative
PCR for the detection of microorganisms in water. Anal Bioanal Chem.
2013;405(1):91–108.
30. Pinheiro LB, Coleman VA, Hindson CM, Herrmann J, Hindson BJ, Bhat S,
Emslie KR. Evaluation of a droplet digital polymerase chain reaction format
for DNA copy number quantification. Anal Chem. 2012;84(2):1003–11.
31. Huggett JF, Foy CA, Benes V, Emslie K, Garson JA, Haynes R, Hellemans J,
Kubista M, Mueller RD, Nolan T, et al. The digital MIQE guidelines: minimum
information for publication of quantitative digital PCR experiments. Clin
Chem. 2013;59(6):892–902.
32. Zhao H, Wilkins K, Damon IK, Li Y. Specific qPCR assays for the detection of
orf virus, pseudocowpox virus and bovine papular stomatitis virus. J Virol
Methods. 2013;194(1–2):229–34.
33. Brunetto GS, Massoud R, Leibovitch EC, Caruso B, Johnson K, Ohayon J,
Fenton K, Cortese I, Jacobson S. Digital droplet PCR (ddPCR) for the precise
quantification of human T-lymphotropic virus 1 proviral loads in peripheral
blood and cerebrospinal fluid of HAM/TSP patients and identification of
viral mutations. J Neurovirol. 2014;20(4):341–51.
34. Zhao S, Lin H, Chen S, Yang M, Yan Q, Wen C, Hao Z, Yan Y, Sun Y, Hu J,
et al. Sensitive detection of Porcine circovirus-2 by droplet digital
polymerase chain reaction. J Vet Diagn Invest. 2015;27(6):784–8.
35. Racki N, Dreo T, Gutierrez-Aguirre I, Blejec A, Ravnikar M. Reverse
transcriptase droplet digital PCR shows high resilience to PCR inhibitors
from plant, soil and water samples. Plant Methods. 2014;10(1):42.
36. Huggett JF, Novak T, Garson JA, Green C, Morris-Jones SD, Miller RF,
Zumla A. Differential susceptibility of PCR reactions to inhibitors: an
important and unrecognised phenomenon. BMC Res Notes. 2008;1:70.
37. Doi H, Takahara T, Minamoto T, Matsuhashi S, Uchii K, Yamanaka H. Droplet
digital polymerase chain reaction (PCR) outperforms real-time PCR in the
detection of environmental DNA from an invasive fish species. Environ Sci
Technol. 2015;49(9):5601–8.
38. Hindson BJ, Ness KD, Masquelier DA, Belgrader P, Heredia NJ, Makarewicz
AJ, Bright IJ, Lucero MY, Hiddessen AL, Legler TC, et al. High-throughput
droplet digital PCR system for absolute quantitation of DNA copy number.
Anal Chem. 2011;83(22):8604–10.
39. Rami-Porta R, Crowley JJ, Goldstraw P. The revised TNM staging system for
lung cancer. Ann Thorac Cardiovasc Surg. 2009;15(1):4–9.
40. Jarry J, Schadendorf D, Greenwood C, Spatz A, van Kempen LC. The validity
of circulating microRNAs in oncology: five years of challenges and
contradictions. Mol Oncol. 2014;8(4):819–29.
41. Haque KA, Pfeiffer RM, Beerman MB, Struewing JP, Chanock SJ, Bergen AW.
Performance of high-throughput DNA quantification methods. BMC
Biotechnol. 2003;3:20.
42. Bustin S, Dhillon HS, Kirvell S, Greenwood C, Parker M, Shipley GL, Nolan T.
Variability of the reverse transcription step: practical implications. Clin Chem.
2015;61(1):202–12.
43. Dellett M, Simpson DA. Considerations for optimization of microRNA PCR
assays for molecular diagnosis. Expert Rev Mol Diagn. 2016;16(4):407–14.
44. Huggett JF, Cowen S, Foy CA. Considerations for digital PCR as an accurate
molecular diagnostic tool. Clin Chem. 2015;61(1):79–88.
45. Hindson CM, Chevillet JR, Briggs HA, Gallichotte EN, Ruf IK, Hindson BJ,
Vessella RL, Tewari M. Absolute quantification by droplet digital PCR versus
analog real-time PCR. Nat Methods. 2013;10(10):1003–5.
46. Miotto E, Saccenti E, Lupini L, Callegari E, Negrini M, Ferracin M.
Quantification of circulating miRNAs by droplet digital PCR: comparison of
EvaGreen- and TaqMan-based chemistries. Cancer Epidemiol Biomarkers
Prev. 2014;23(12):2638–42.
47. Dingle TC, Sedlak RH, Cook L, Jerome KR. Tolerance of droplet-digital
PCR vs real-time quantitative PCR to inhibitory substances. Clin Chem.
2013;59(11):1670–2.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Campomenosi et al. BMC Biotechnology  (2016) 16:60 Page 10 of 10
